SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
Phase of Trial: Phase IV
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Empagliflozin (Primary)
- Indications Hypertension; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SACRA Study
- 25 Mar 2018 Status changed from recruiting to completed.
- 13 Feb 2017 New trial record
- 10 Feb 2017 Status changed from not yet recruiting to recruiting.